Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.
about
Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study.Population pharmacokinetic analysis of piperacillin in burn patientsPopulation pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimensThe effect of sepsis upon gentamicin pharmacokinetics in neonates.SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patientsPK/PD analysis of biapenem in patients undergoing continuous hemodiafiltration.Regulation of drug metabolism and disposition during inflammation and infection.Safety and efficacy of albumin administration in trauma.Population pharmacokinetics of dexmedetomidine in critically ill patientsIdeal microbiological and pharmacological characteristics of a quality antimicrobial agent: comparing original and generic molecules.Impact of lipopolysaccharide-induced inflammation on the disposition of the aminocephalosporin cefadroxil.Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis.Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients.Pharmacological rationale for antibiotic treatment of intra-abdominal infections.The role of hepatic cytochrome P-450 in sepsis.A review of psychophysiological stressors on pharmacokinetics.Methadone: a review of drug-drug and pathophysiological interactions.Haloperidol dosing strategies in the treatment of delirium in the critically ill.Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis.Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm.Metabolic and toxicological considerations for sepsis drug treatments.Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis.Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies.Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients.The pharmacokinetics of propofol in ICU patients undergoing long-term sedation.Effect of fluid loading during hypovolaemic shock on caspofungin pharmacokinetic parameters in pig.Effects of Low-Dose Escherichia coli Lipopolysaccharide-Induced Endotoxemia on Morphine Pharmacokinetics in an Animal Model.[Strategies for antifungal treatment failure in intensive care units].Optimal study design for pioglitazone in septic pediatric patients.Optimal aminoglycoside therapy following the sepsis: how much is too much?Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.Pharmacokinetics of fexofenadine following LPS administration to rats.FXa inhibition and coagulation changes during DVT prophylaxis by enoxaparin over the course of a 15-day follow-up in septic patients.Pharmacokinetics of intravenous polymyxin B in critically ill patients.Propofol clearance and volume of distribution are increased in patients with major burns.Adjunctive use of physostigmine salicylate (Anticholium®) in perioperative sepsis and septic shock: study protocol for a randomized, double-blind, placebo-controlled, monocentric trial (Anticholium® per Se).Febuxostat protects rats against lipopolysaccharide-induced lung inflammation in a dose-dependent manner.Effect of Abrupt Discontinuation of Antidepressants in Critically Ill Hospitalized Adults.The pharmacokinetics of vancomycin in patients with severe acute pancreatitis.Accuracy of the estimation of glomerular filtration rate within a population of critically ill patients.
P2860
Q24813384-F1BB57DA-C766-4637-BA83-D73B9590EEEFQ33798377-C77849A9-2FB7-423C-BD4F-19F87E03D8D3Q34570886-E2BA1CA3-3762-4E02-AAC8-8FF1074ADA72Q35827298-091DB02A-FB6F-46D2-92A8-CD1E5A4C47B2Q35942407-B63A17EC-0DCF-4D85-99A7-735200A71335Q36507959-CB5EC251-51FF-429D-A851-0252549A72C6Q36544874-7E82D17A-9C04-4BC7-9496-1D3F71BB92C4Q36905851-FFAC6C92-3EF7-4BDE-9D0A-9CB75FD2614BQ37028968-77221200-AF7F-4C3F-B705-36170A43CD36Q37071315-56635E26-6692-4072-98D9-0B27C19EE2DDQ37335874-F38F97E1-C8DB-44CD-912F-428B206801E2Q37461431-87CE382A-DEA5-48F9-9B9C-6A9F6DA75858Q37544453-CF9DF677-2D8D-4CB0-BD52-4CF0FECF4CF4Q37557851-1EA119D2-85F3-4E65-A331-FDB773A82778Q37633942-5CF68490-185B-45D2-9547-FECFBF8EA324Q37831732-A2052BFA-17E6-451F-8593-6CBCF7A51D1BQ37950478-06B7B011-F511-47BC-AB16-21ABC3C3BD55Q37950933-4109DF47-3F56-45C6-A5C5-9E3B5D1A5175Q38000242-00C677A2-EFD5-469E-AE20-404E4100AE3CQ38040844-F5ECB3C2-5EF9-45A2-85C5-6015FB334CD5Q38045406-C75E0B76-6204-478A-80F7-547AC144A857Q38164685-27B44315-C648-410C-BF75-C7B2797EA91BQ38850670-92A46444-8B3A-4B56-9C04-438E3088643EQ39048274-CEA5A8FA-674B-46BF-AFDF-47DBB65F1F57Q39457828-082241B9-F3DB-4910-887F-B47821B612BBQ39705805-7E591D58-B8C4-4475-B83F-9FC80C3481E6Q40057969-7BEDCB2A-A4EA-4E41-93CE-1FE09B2F2332Q41010354-3B0A331F-AC19-456A-82D0-1DC4A14C26B5Q41585973-D27754F3-6830-47AA-B04C-61916E2FE8F7Q41963116-DBA6AF6B-C52D-4813-90A3-86D41E34571EQ42654588-6E2F7ACB-AD46-4693-BC84-987F4DA43F54Q42878442-B32C2096-73BC-4ECB-8646-C4F716630278Q43256509-323DD396-FB0F-446F-BA4D-559D4B9FB97BQ44808038-379DB6DD-3C78-42E4-892F-646D899E93DEQ45954226-89DB227C-C68D-440B-B576-4F051C281AA5Q46174594-E8610722-DA75-4FC0-A6B4-3A27896C252CQ46225596-EB8D3A8D-5E89-4FFB-A4CD-2D001912F1B6Q47690776-13A0F284-0482-4ECF-AE49-6C03C585637BQ50707463-239910BB-CC17-4A74-9F4F-FEF1F2A90349Q51121630-8C5BA77D-3B3B-4121-BC60-5BDD1F7904EA
P2860
Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Pharmacokinetic and pharmacody ...... with sepsis and septic shock.
@ast
Pharmacokinetic and pharmacody ...... with sepsis and septic shock.
@en
Pharmacokinetic and pharmacody ...... with sepsis and septic shock.
@nl
type
label
Pharmacokinetic and pharmacody ...... with sepsis and septic shock.
@ast
Pharmacokinetic and pharmacody ...... with sepsis and septic shock.
@en
Pharmacokinetic and pharmacody ...... with sepsis and septic shock.
@nl
prefLabel
Pharmacokinetic and pharmacody ...... with sepsis and septic shock.
@ast
Pharmacokinetic and pharmacody ...... with sepsis and septic shock.
@en
Pharmacokinetic and pharmacody ...... with sepsis and septic shock.
@nl
P2093
P1476
Pharmacokinetic and pharmacody ...... with sepsis and septic shock.
@en
P2093
Frans M Belpaire
Peter De Paepe
Walter A Buylaert
P304
P356
10.2165/00003088-200241140-00002
P577
2002-01-01T00:00:00Z
P5875
P6179
1013861976